Australia’s technology transfer ecosystem is unusual among national models in one respect: its largest single source of licensable, spinout-ready IP is not a university at all, but a government research agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO). Around that agency has grown a distinctly Australian mix of university-run venture funds, a national accelerator pipeline, and a federal policy programme — the University Research Commercialisation Action Plan — explicitly designed to close the gap between Australia’s strong research output and its historically weaker record of turning that research into companies.
This guide covers how the pieces fit together: CSIRO’s dual role as researcher and investor, the university spinout funds that have spread across roughly half of Australia’s universities, the accelerator programmes that feed deals into those funds, and the federal policy architecture that has funded and coordinated all of it since 2022.
CSIRO’s dual role: national research agency and venture investor
CSIRO is Australia’s national science agency, established by federal statute and funded primarily through Commonwealth appropriation, with its own substantial patent portfolio built up over decades of applied research. Unlike a typical university technology transfer office, which licenses IP arising mainly from academic staff and students, CSIRO both generates the IP itself (as a mission-driven research performer) and, since 2016, has run a dedicated venture capital arm to commercialise it.
That arm, Main Sequence Ventures, was seeded by the CSIRO Innovation Fund, which combined AUD 70 million in Commonwealth Government funding with a further AUD 30 million contributed from CSIRO’s own royalty income — most notably from CSIRO’s wireless LAN (Wi-Fi) patents, one of the most consequential patent-licensing programmes in Australian research history, which generated well over AUD 200 million in royalties from global technology companies over more than a decade of licensing and litigation. That royalty stream is the origin story venture-capital observers in Australia most often cite when explaining why a government research agency, rather than a bank or a university, ended up running one of the country’s largest deep-tech funds.
Main Sequence Ventures has since grown well beyond that initial seed capital. It now manages more than AUD 1 billion across its funds, and its third fund reached a first close of roughly AUD 450 million (about USD 305 million). It invests in deep-tech and science-based startups broadly, not only those spun out of CSIRO, but CSIRO-originated IP remains a structurally important part of its deal flow, and CSIRO itself remains a cornerstone investor and namesake sponsor of the fund.
This government-research-institute-as-commercialisation-engine structure has a closer analogue elsewhere in the Asia-Pacific region than it does among CASRAI’s European or North American case studies: see Taiwan’s ITRI vs. Singapore’s A*STAR for how two other governments built national applied-research institutes with their own commercialisation arms, running in parallel to (rather than instead of) their university tech transfer systems — structurally the closest comparison to CSIRO’s role in Australia, though Main Sequence Ventures’ fund-management model differs from ITRI’s spinoff-and-licensing approach and A*STAR’s more centrally directed commercialisation function.
University spinout funds: now at roughly half of Australian universities
Alongside CSIRO’s national-scale activity, individual Australian universities have built their own dedicated investment vehicles for spinning research out into companies. Industry reporting tracking university venture funds globally has found that roughly 25 of Australia’s 43 academic institutions now have access to a dedicated investment fund that can support spinouts emerging from their research — a materially higher proportion than in the United States (where roughly a third of top research universities have such a fund) or Europe (roughly 40 percent).
Two structures dominate the Australian landscape:
- Multi-university consortium funds. Uniseed, launched in 2000 with an initial AUD 20 million contributed by the University of Queensland’s commercialisation arm (UniQuest) and the University of Melbourne’s Melbourne Enterprises International, is the longest-running example. It now manages a roughly AUD 50 million early-stage fund on behalf of a consortium of universities — Melbourne, Queensland, Sydney, UNSW, and Monash among its investor institutions — plus a separate roughly AUD 100 million co-investment vehicle run jointly with the industry pension fund UniSuper. Brandon BioCatalyst plays a similar consolidating role specifically for the life sciences, structured as a partnership among biotech company CSL, Australian pension funds, state governments, the Australian and New Zealand federal governments, and more than 50 affiliated medical research institutes; around 14 institutions have access to it.
- Single-university funds. A growing number of individual universities — UNSW and the University of Sydney among the most active in recent fundraising and deal volume — run their own dedicated spinout or venture funds rather than relying solely on a consortium vehicle, giving them more direct control over cap-table terms and follow-on investment decisions on their own research-derived startups.
The practical effect of this fund density is that an Australian researcher whose invention clears a university’s or CSIRO’s initial commercialisation screen is more likely than counterparts in most other countries to find dedicated, sector-specific early-stage capital already sitting inside (or one call away from) their own institution, rather than having to go directly to generalist venture capital with an unproven, pre-revenue technology.
The University Research Commercialisation Action Plan (2022)
The current federal policy framework tying these pieces together is the University Research Commercialisation Action Plan, announced by the Australian Government in February 2022 as a AUD 2.2 billion package of reforms and funding delivered over 11 years. Administered through what is now the Department of Education, the plan was framed as a response to a long-documented weakness in Australia’s innovation system: strong per-capita research output and citation impact, but comparatively low rates of translating that research into commercial ventures, licensing revenue, and industry collaboration, relative to OECD peers.
The plan’s headline commitments include:
- Australia’s Economic Accelerator (EA) Program — a roughly AUD 1.6 billion grants programme providing staged, non-dilutive funding (from early-stage proof-of-concept through to commercial-scale-up) to move university and public-sector research through the stages venture capital typically won’t fund until a technology is de-risked.
- Trailblazer Universities Program — funding for a small number of universities to build deep, sustained industry-research partnerships in specific national priority areas (such as advanced manufacturing, resources technology, and food/agtech), rather than spreading commercialisation support thinly across every discipline.
- National Industry PhD Program — co-funded, industry-embedded doctoral training intended to build a workforce that moves between university research and commercial application, rather than treating industry placement as incidental to a research degree.
- Expansion of CSIRO’s Main Sequence Ventures — additional Commonwealth capital directed into the fund described above, explicitly justified as scaling a commercialisation vehicle that had already demonstrated it could convert public research investment into follow-on private capital.
Two things are worth flagging for researchers and research administrators reading this from outside Australia. First, the plan is explicitly a multi-year package rather than a single grant round: its AUD 2.2 billion is committed across 11 years, so individual programme rounds (EA grant calls, Trailblazer cohort intakes) open and close on their own schedules rather than as one lump disbursement. Second, the plan sits on top of, rather than replacing, the pre-existing university and CSIRO commercialisation infrastructure described above — Uniseed, Brandon BioCatalyst, and CSIRO’s Main Sequence Ventures all predate 2022; the Action Plan is best understood as a federal coordination and capital-injection layer on an ecosystem that already had working parts, not a ground-up redesign of it.
ON Prime and ON Accelerate: CSIRO’s national accelerator pipeline
Sitting alongside (and increasingly integrated with) the Action Plan’s funding programmes is CSIRO’s own longer-running national accelerator offering, delivered under the ON brand and open to publicly funded researchers from any Australian institution, not just CSIRO staff:
- ON Prime is a free, part-time pre-accelerator aimed at research teams who have not yet validated a commercial application for their work. It runs in two annual cohorts (roughly April–June and August–October), combining in-person and online sessions across a nine-week programme, and typically supports around 100 research teams a year across all disciplines.
- ON Accelerate is the follow-on, full-time, three-month accelerator for teams with a validated concept who are ready to build a business model, pursue capital raising, and prepare an investor-facing pitch. CSIRO reports that ON Accelerate alumni have collectively gone on to form more than 70 new companies and raise well over AUD 300 million in follow-on commercialisation grants and investment.
Functionally, ON Prime and ON Accelerate act as the talent-and-deal-flow pipeline that feeds the capital sitting in Main Sequence Ventures, Uniseed, Brandon BioCatalyst, and individual university funds: a research team typically moves from invention disclosure, through a university’s or CSIRO’s internal commercialisation screen, into ON Prime to test the market case, then into ON Accelerate to build investor readiness, before approaching spinout-fund or venture capital for a priced round. Not every team follows that exact sequence, and plenty of Australian spinouts are formed without ever touching the ON programme, but it is the closest thing Australia has to a standardised, government-backed on-ramp from lab bench to cap table.
Measuring outcomes: the SCOPR survey
Unlike some national systems, Australia does not have a single government-mandated annual disclosure count in the way the United States’ AUTM Licensing Survey has become a de facto national benchmark. The closest Australian and New Zealand equivalent is the Survey of Commercialisation Outcomes from Public Research (SCOPR), run annually by the sector body Knowledge Commercialisation Australasia (KCA). SCOPR aggregates self-reported commercialisation activity — active equity spinouts, licensing deals, invention disclosures, and related metrics — across Australian and New Zealand universities, medical research institutes, and public research agencies including CSIRO, and is the primary source institutions and policymakers cite when comparing performance across the sector, including tracking the effect of Action Plan funding over time.
How the Australian model differs from other systems
For readers comparing Australia against the other national models CASRAI covers in this series:
- Vs. the government-research-institute model (Taiwan/Singapore): like Taiwan’s ITRI and Singapore’s A*STAR, CSIRO is a government-funded applied-research body that commercialises its own IP directly — but CSIRO does so primarily through a fund-management vehicle (Main Sequence Ventures) that also invests in non-CSIRO deep-tech startups, rather than through ITRI’s spin-off-company model or A*STAR’s more centrally coordinated licensing function.
- Vs. the centralised regional-agency model (France): France’s SATT network consolidates early-stage commercialisation for clusters of universities into regional companies with a single national mandate; Australia’s Uniseed and Brandon BioCatalyst are voluntary, university-owned consortium funds rather than a government-mandated regional structure, and individual universities are free to run their own funds instead of or alongside a consortium.
- Vs. the applied-research-institute model (Germany): Germany’s Fraunhofer-Gesellschaft is funded to perform contract applied research for industry as its core mission, with commercialisation embedded in that funding model; CSIRO performs a broader, more general scientific mission and layers venture investment on top of it as one commercialisation route among several (licensing, contract research, and spinouts all coexist).
- Vs. the devolved university-TTO model (UK, Canada): Australia resembles the UK’s Research England/shared-TTO model and Canada’s institution-by-institution NSERC/IP model in leaving IP ownership and TTO structure largely to individual universities, but goes further with the density of dedicated spinout funds sitting directly under those TTOs.
Frequently asked questions
Is CSIRO a university?
No. CSIRO (the Commonwealth Scientific and Industrial Research Organisation) is Australia’s national science agency, established by federal legislation and funded primarily through Commonwealth Government appropriation. It performs its own mission-directed research programmes independently of the university sector, though it frequently collaborates with universities, and its commercialisation infrastructure (including Main Sequence Ventures) is separate from any individual university’s technology transfer office.
What is Main Sequence Ventures, and who can it invest in?
Main Sequence Ventures is a venture capital fund manager originally seeded by the CSIRO Innovation Fund and closely associated with CSIRO, but it invests in Australian deep-tech and science-based startups broadly — not exclusively in companies spun out of CSIRO’s own research. It now manages more than AUD 1 billion across multiple funds.
Do all Australian universities have a dedicated spinout fund?
No, but a substantial majority-adjacent share does. Industry tracking puts the figure at roughly 25 of Australia’s 43 academic institutions with access to a dedicated investment fund, either through a multi-university consortium vehicle (such as Uniseed or Brandon BioCatalyst) or a fund run by a single university. That proportion is reported to be higher than in the United States or Europe.
How does the University Research Commercialisation Action Plan relate to CSIRO’s ON programmes?
They are administratively distinct but functionally connected. ON Prime and ON Accelerate are longer-running CSIRO programmes that predate the 2022 Action Plan; the Action Plan is a broader, Department of Education-administered federal funding package (Australia’s Economic Accelerator, Trailblazer Universities, the National Industry PhD Program, and expanded funding for Main Sequence Ventures) that sits alongside CSIRO’s existing accelerator pipeline rather than having created it from scratch.
Where can I find comparable data on Australian university spinout activity?
The Survey of Commercialisation Outcomes from Public Research (SCOPR), run annually by Knowledge Commercialisation Australasia (KCA), is the standard sector-wide benchmark covering Australian and New Zealand universities, medical research institutes, and public research agencies.
